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Background: Abnormal uterine bleeding is often investigated in clinical studies and critical to identify during
gynecological consultation. The current standard for quantification of menstrual blood loss is the alkaline-hematin-
method. However, this method is expensive and inconvenient for patients. Bleeding diaries, although widely used,
provide only qualitative information on menstrual blood loss. Other methods have been developed, but still do not
provide reliable quantitative data.
Methods: We estimated blood loss volume using data from two clinical studies in women suffering abnormal
menstrual bleeding. These estimations were derived from mixed linear models based on diary data, hematological
parameters and age. To validate the models, we applied our results to data from a third study with a similar patient
population.
Results: The resulting best fitting model uses diary entries on bleeding intensity at a particular day, information on
occurrence and frequency of single bleeding intensities in defined time windows, hemoglobin and ferritin values
and age of the patient all as predictors of menstrual blood loss volume. Sensitivity and specificity for the diagnosis of
excessive bleeding were 87% and 70%, respectively. Our model-based estimates reflect the subjective assessment by
physicians and patients in the same way as the measured values do.
When applying the model to an independent study, we found a correlation of 0.73 between estimated and
measured values for the blood loss in a single day. Further models with reduced number of parameters (simplified
for easier practical use) still showed correlation values between 0.69 and 0.73.
Conclusions: We present a method for estimating menstrual blood loss volume in women suffering from prolonged
or excessive menstrual bleeding. Our statistical model includes entries from bleeding diaries, laboratory parameters
and age and produces results which correlate well with data derived by the alkaline-hematin-method. Therefore, this
model may be used to estimate menstrual blood loss volume in both routine gynecological counseling and clinical
studies.Background
Abnormal uterine bleeding is an important clinical topic
both within clinical studies and during gynecological
consultation [1-3]. Changes in bleeding intensity or intra-
cyclic bleeding might be symptoms of pathological pro-
cesses. Dysfunctional uterine bleedings, including heavy,
frequent and prolonged bleedings may not only sub-
stantially decrease quality of life, but can also cause* Correspondence: ulrike.schumacher@med.uni-jena.de
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distribution, and reproduction in any mediumiron-deficiency anemia [4,5]. A menstrual diary is the
most commonly used tool to monitor menstrual blood
loss, and the WHO has defined the main principles used
to evaluate vaginal bleedings from diaries [6]. To supple-
ment these principles, Gerlinger et al. have proposed new
standards for diary evaluation [7,8].
However, single bleeding episodes remain incommen-
surable and menstrual blood loss volume (MBLV) is diffi-
cult to estimate based on diaries. The current standard
for quantification of menstrual blood loss is the alkaline-
hematin-method [9], for which women need to collect
and date all sanitary protection items for laboratory analysis.
Recently, the method was extended to a semi-automatedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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absorbing materials [10]. However, this method remains
both expensive and inconvenient.
Methods based on direct measurement of sanitary item
weight change [11,12] are inherently imprecise because
blood fraction accounts for only about 30 – 40% of men-
strual fluid and this portion is highly variable between
individuals [13,14].
Semi-quantitative assessment of blood loss by com-
paring sanitary item stain with given diagrams (Pictorial
Blood Loss Assessment Chart, PBAC) [15] is another
method to assess blood loss. Using an appropriate cut-
off point, Janssen et al. reported predictive values with
respect to menorrhagia up to 85.9% for positive tests and
84.9 for negative tests [16]. Unfortunately reproducibility
of results of PBAC was challenged [17]. Nonetheless, a
recent study found that PBAC is a simple and accurate
tool for semi-objective measurement of menstrual blood
loss [18]. The correlation between pictorial assessment
results and values measured by the alkaline-hematin-
method is quite good, however the amount of blood not
captured by sanitary items is considerable [19]. Other
bleeding characteristics such as the number of sanitary
items used highly depend on the socio-economic status
and the individual hygienic needs of women [20].
We think that a tool to estimate menstrual blood loss
based on diaries and additional routine laboratory param-
eters would be very helpful. A first comparison of MBLV
as measured by alkaline-hematin-method with diary en-
tries in women with menorrhagia by Fraser et al. [21]
yielded mean values for the different categories. However,
individual ranges were wide and Fraser et al. concluded
that only alkaline hematin extraction provides reliable
assessments of menstrual blood loss volume. However,
these estimates were based solely on arithmetic means
and did not account for patient-specific differences in
menstrual diary entries. The perception of menstrual
blood loss is highly subjective. The idea of the present
analysis was to derive information on the woman’s indi-
vidual “assessment range” using additional parameters
such as hematological values (hemoglobin, ferritin) which
are routinely measured in clinical studies, other diary
characteristics (e.g. number of days with the different
intensities), age and possibly other influencing factors.
In order to develop a statistical model that provides
improved estimation of MBLV based on menstruation
diaries and accounting for additional parameters, we




We retrospectively analyzed diary data on bleeding
intensities from two prospective studies investigatingtreatment of dysfunctional uterine bleeding with an oral
contraceptive containing estradiol valerate/dienogest in
order to derive estimates of MBLV. Details on the study
results have been published earlier: Study 1: [22], Study
2: [23].
A third prospective study on treatment of idiopathic
menorrhagia with a levonorgestrel containing intra-
uterine device (IUS) versus Medroxyprogesterone acetate
retrospectively served to validate our findings. Details on
the third study have been published elsewhere [24].
All studies were conducted in accordance with all local
legal and regulatory requirements and with the ethical
principles that have their origin in the Declaration of
Helsinki and the ICH-GCP Guidelines. The protocols
and amendments were reviewed and approved by each
site’s Independent Ethics Committee (IEC) or Institu-
tional Review Board (IRB) before the start of the studies
and before implementation of the amendments.
All three studies had a similar design. Patients received
bleeding diaries to record daily bleeding intensity (BI) in
four categories: SPOTTING and LIGHT, NORMAL or
HEAVY bleeding. Days without bleeding and spotting
were marked with „no bleeding“. On days with bleeding
or spotting, sanitary items were collected on a daily basis.
Daily MBLV was determined by applying the alkaline-
hematin-method [9,25].
In addition, hemoglobin, hematocrit and serum ferritin
were measured with standard methods in local laborator-
ies. Blood samples were taken at several time points
during the studies. Intermediate blood values have been
calculated by linear interpolation.
Age was recorded at time of study inclusion.
A bleeding episode was defined as according to
Gerlinger et al. [8] as a period of days with bleeding or
spotting preceded and followed by at least 2 bleed-free
days.
Study population
All three studies included patients with menstrual bleed-
ing abnormalities. The first two studies investigated
women with dysfunctional uterine bleeding defined as
excessive (at least two episodes with a total blood loss
of at least 80 ml MBLV during the reference period of
90 days), frequent (more than 5 episodes with a total of
at least 20 bleeding days during the reference period),
or prolonged (at least 2 episodes of 8 or more days each
during the reference period). The third study, the valid-
ation study, included patients with idiopathic menor-
rhagia, defined as a total blood loss of at least 80 ml
during at least two of three reference cycles. We used
all daily patient data, where information on BI, MBLV,
hematological values and age was available, even of
screening failures who were not included in the original
studies analyses.
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Statistical analysis
Since the distribution of measured MBLV values was
highly skewed, all analyses were performed after logarith-
mic transformation of MBLV values. Transformed values
were approximately normally distributed but with remark-
able differences in variability between categories. This was
accounted for in the model by category-specific variances.
In addition to the BI categories, we considered three
main groups of predictors for MBLV:
 Hematological values (hemoglobin, hematocrit and
serum ferritin)
 Additional diary information apart from BI, i.e.,
frequency of the BI SPOTTING, LIGHT, NORMAL
and HEAVY during several defined time windows
 Age of the patient.
Inclusion of these additional predictors can be inter-
preted as an attempt to quantify subjective, patient-
specific differences in “assessment ranges”. As this can
only partly be achieved, we used a mixed model approach
to account for remaining patient-specific effects (i.e. con-
sistent inter-individual differences in the assignment of
blood loss to categories of bleeding intensity). Our basic
model therefore is a linear mixed model of the form
yik ¼ β1 þ β2x2;ik þ β3x3;ik þ . . .þ βpxp;ik þ γi þ εik
where yik is the MBLV of the i-th patient on day k, βl are
the regression parameters to be estimated, xl;ik are the
respective covariates of patient i at day k , γi denotes
a random effect associated with patient i, assumed to
be normally distributed, and εik is the residual error of
patient i at day k, assumed to be normally distributed
with category-specific variance.
Because subjective threshold values may also lead to
patient-specific differences between categories we add-
itionally included a random patient * BI interaction term.
Model selection proceeded sequentially: Starting with
a model based on BI only, models including different
combinations of laboratory parameters with and without
interaction with BI have been examined, resulting in the
best hematological model.Table 1 Summary of demographic data of the three study po
Study
Number of patients used 190
Number of days 9452
Mean age (± standard deviation) [years] 36.9 (±
Median cycle length (range) [days] 28 (9 –
Mean duration [days] of bleeding episodes (range) 7.6 (4 –In a second step, we considered diary-derived
parameters
 occurrence of each single BI in the current bleeding
episode,
 occurrence of each single BI in the entire diary, and
 number of days reporting each single BI during
several time windows
Possible time frames of interest considered were:
 the actual bleeding episode comprising the day
of interest
 the preceding episode
 all bleeding episodes during a time period most
probably containing the last menstrual/withdrawal
bleeding episode, here assessed as „all episodes
extending at least 1 day into the 30 days preceding
the actual episode“
 a baseline episode which reflects the inclusion
criterion of the studies, defined here as the second
heaviest episode during baseline. Heaviest was
defined according to Fraser et al. [21] by using the
means for MBLV per BI given there as a rough
estimation.
In this step we initially searched for the best diary-
parameter / time-frame combination separately for each
single BI and subsequently considered combinations of
those models incorporating information about several BI.
In the third step we added age to the model.
However, since the best model (M1, see results) con-
tains several parameters probably not always available,
we considered in addition a number of reduced models
for more practical use.
 (M2) accounts for 1) number of days with heavy
bleeding, 2) occurrence of normal bleeding, 3)
occurrence of light bleeding and 4) occurrence of
spotting. All parameters were assessed with respect
to the actual bleeding episode. Furthermore, we
included 5) hemoglobin (Hb), 6) serum-ferritin
(Fe, including interaction with BI) and 7) age.
 (M3) accounts for the laboratory parameters only
as given in (M1),pulations
1 Study 2 Validation study 3
250 162
12431 3242
7.1) 39.2 (± 6.9) 38.8 (± 5.3)
38) 28 (14 – 38) 28 (7 – 33)
60) 6.9 (3 – 17) 6.3 (3 – 14)














57861.7 - - -
(M1) 55740.0 2514.4 42 <0.001
(M2) 55781.7 2379.8 30 <0.001
(M3) 55837.6 2114.0 9 <0.001
(M4) 55881.3 2290.2 31 <0.001
(M5) 55925.1 2016.5 8 <0.001
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in (M1),
 (M5) accounts for age only.
All models include the BI of the respective bleeding
day.
All models were analyzed on the basis of data from
study 1 and 2 and were compared using Bayes’ Infor-
mation Criterion, BIC [26]. Here smaller values of this
criterion indicate more adequate statistical models. Com-
putations were performed using SAS software package
(SAS Institute Inc., Cary, NC, USA) version 9.1.3 under
Windows (Version 5.1).
We validated our models by using the data of study 3.
For evaluation of reproducibility, we calculated the
Spearman correlation coefficient between estimated
MBLV and measured MBLV. For evaluation of medical
relevance, we compared change of blood loss - estimated
and measured MBLV - with the patient’s efficacy assess-
ment by using the Global Improvement Item of the Clin-
ical Global Impression Score (CGI) [27].
For practical use, assessment of bleeding episodes with
excessive bleeding is of major clinical interest. Therefore,
sensitivity and specificity of assessment via estimated
MBLV versus assessment via measured MBLV values as
gold standard were evaluated.
Results
For laboratory parameters, the best model (M1) includes
 hemoglobin and
 serum-ferritin including BI interaction.
The inclusion of hematocrit did not lead to improve-
ment of the model.
Evaluation of diary parameters leads to the best model
containing:
 number of days with HEAVY bleeding in the current
bleeding episode
 number of days with HEAVY bleeding in the
preceding bleeding episode
 occurrence of HEAVY bleeding in the entire
diary
 mean number of days with NORMAL bleeding
during all episodes reaching into the last 30 days
before current episode
 number of days with NORMAL bleeding in the
second heaviest baseline-episode
 number of days with LIGHT bleeding in the second
heaviest baseline-episode
 occurrence of LIGHT bleeding in the current
episode
 occurrence of SPOTTING in the current episodeExamination of the
 age of the patient
resulted in a model including also interaction of age
with BI.
Permutation of implementation of these three blocks
of parameters confirmed necessity of all. Table 2 gives
values of BIC for the best and the reduced models. Esti-
mates and their standard errors for models (M1) to (M5)
are listed in the Additional file 1.
The BIC values of the different models clearly show
the advantage of model (M1). Each further simplifica-
tion (M2) – (M5) results in worse model indicated by an
increase of the BIC. However, all models have a very clear
advantage with respect to the model without any sup-
portive parameters which is also confirmed by likelihood
ratio tests comparing (M1) – (M5) to the initial model.Validation
For the validation study, we compared estimated values
based on model (M1), given as mean of estimated MBLV
values (geometric mean / median), with values measured
by means of alkaline-hematin-method (measured values).
The estimated MBLV value for days with spotting was
3.23 ml (2.19 ml / 3.16 ml); while the measured value
was 3.04 ml (1.65 ml / 1.10 ml). For days with light bleed-
ing, the estimated value was 7.52 ml (6.36 ml / 7.27 ml)
and the measured value was 9.23 ml (4.70 ml / 4.00 ml).
We estimated blood loss on days with normal bleeding
as 31.57 ml (29.36 ml / 30.05 ml) and measured blood
loss as 30.39 ml (18.21 ml / 22.10 ml). On days with
heavy bleeding the estimated value was 70.25 ml
(67.44 ml / 68.42 ml), whereas the measured figure was
60.86 ml (48.01 ml/ 51.20 ml) in the validation study.
The Spearman correlation coefficient (standard error)
between single estimated and measured values was
0.73 (0.012) with p < 0.0001. When comparing com-
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Figure 1 Validation study, mean and difference of measured
and estimated MBLV values.
Table 4 Comparison of change in bleeding amount with
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sums was 0.62 (0.031) with p < 0.0001.
Application of model (M2) resulted in only slightly
changed estimates. Spearman correlation remains
0.73 (0.012) with p < 0.0001 for day-wise comparison and
0.64 (0.030) with p < 0.0001 for the episodes. Even with
the most simple model (M5), the correlation between
day-wise estimates and measurements was 0.69 (0.012)
(Table 3).
A Bland-Altman-Plot [28] relating the difference
between measured and estimated values to the mean
of both quite well illustrated the results (display of log-
transformed values). Within individual categories values
were equalized, low values were overestimated and high
values underestimated. Generally, estimated values were
slightly higher than measured. There was a clear separ-
ation between SPOTTING and LIGHT bleeding on the
one hand and NORMAL and HEAVY bleeding on the
other hand (Figure 1).
Both, estimated and measured MBLV values, were used
to predict patients and investigators subjective impres-
sion of treatment effect [27], assessed as change from
a baseline phase (56 days pretreatment) to final phase
(last 56 days under treatment). Estimated and measured
values were almost equivalent and showed similar correl-
ation with the patient’s subjective impressions (Table 4).
In the validation study, a total of 648 episodes were
available and could be used to investigate the classifi-
cation sensitivity and specificity for excessive bleeding
episodes.
When used for classification of bleeding episodes as
excessive, our estimation identified 380 of 435 excessive
episodes (according to the definition based on measured
MBLV), corresponding to a sensitivity of 87%. Of the 213
not excessive episodes (based on measured MBLV) 149
were classified as not excessive based on the estimated
MBLV as well. This provides a specificity of 70% (see
Table 5).
Discussion
Assessment of menstrual blood loss is a ubiquitous topic
in the context of clinical studies that investigate effects ofTable 3 Spearman correlation between estimated and





(M1) 0.73 (0.012) 0.62 (0.031)
(M2) 0.73 (0.012) 0.64 (0.030)
(M3) 0.72 (0.012) 0.60 (0.032)
(M4) 0.70 (0.013) 0.54 (0.033)
(M5) 0.69 (0.012) 0.58 (0.032)
(s.e. = standard error).drugs and devices on menstrual bleeding pattern as well
as in routine gynecological counseling. The current
method of choice is the alkaline-hematin-method [9].
Although this method sees broad use and is the exactest
method available, it is cumbersome, inconvenient and
expensive. On the other hand, menstruation diaries,
although widely used, do not provide sufficient quantita-
tive resolution to compare MBLV of different bleeding
episodes. Semi-quantitative assessment methods like
the PBAC [15] show good sensitivity and specifity for
menorrhagia with respect to the alkaline-hematin-
method [16]. Unfortunately they are not completely pre-
cise, in particular with respect to blood lost outside























−11.79 ± 20.51 0.42 (0.087) 0.43 (0.086)
(s.e. = standard error).



















Total 435 (67.1%) 213 (32.9%) 648 (100%)
(n = 648 episodes; excessive means Sum MBLV of episode > 80 ml).
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available from diaries, we show here that a model-based
statistical estimate of menstrual blood loss can be derived.
By including laboratory parameters (hemoglobin and serum
ferritin) and age we present here simple and accurate
methods for estimation of MBLV.
Estimated MBLV values determined by our model
showed a remarkable correlation of 0.73 to measured
values, when we validated the model using a third study.
A sensitivity of 87.4% and a specificity of 69.9% for
assessment of excessive bleedings are sufficient for clin-
ical use.
Beside the bleeding intensity, the following auxiliary
parameters provide valuable information:
Hematological parameters
Low hemoglobin values and ferritin values can be indica-
tors of substantial menstrual blood loss, sometimes lead-
ing to adaptation and hence higher thresholds for the
bleeding categories. The estimates especially for days
with a blood loss more than SPOTTING increase with
decreasing hemoglobin and ferritin, in agreement to the
findings of Hallberg et al. [5].
Number of days with the certain BIs and occurrence of
the single BIs in defined time windows
In general, the frequency of the single BIs in the diary
gives some insight into the woman’s individual assess-
ment behavior. Extensive usage of the category “HEAVY”
in a given episode can be a sign for having a lower per-
sonal threshold for this BI. On the other hand, if a
woman has had many days of heavy bleeding in her men-
strual history, this may result in increasing personal
thresholds for MBLV classified as heavy. This may be due
to acclimatization to a certain amount of blood loss.
In the event that a single BI is completely missing in
an episode or in the whole diary, a typical effect can be
observed: Here the other BIs tend to fill in the gap. If
HEAVY is not used at all, all other BIs correspond to a
higher level of blood loss, if SPOTTING is missing, thevalues of LIGHT, but also NORMAL decrease, and if
LIGHT is absent, SPOTTING values rise and NORMAL
and HEAVY decrease.
Age
Hallberg et al. and Fraser et al. [5,21] reported an
increasing MBLV with increasing age. Consequently,
women get familiar with their MBLV and the estimates
for the single BIs increase with age.
Modeling the MBLV based on diary BI readings
showed, that the BIs are not equally spaced, on either a
direct or logarithmic scale. Rather there is a more clear
separation between LIGHT and NORMAL bleeding than
within the pairs SPOTTING-LIGHT and NORMAL-
HEAVY, respectively.
Fraser et al. [21] emphasizes that the values of MBLV
scatter notably within the single BI and that these values
might even be contradictory. In agreement with this
observation, we also see that, as in every large data
pool, implausible values occur. Beside false values, which
might be due to entry errors, a considerable segment of
variability is due to individual differences. We were able
to reduce this segment of variability by including add-
itional information on the bleeding behavior, laboratory
parameters and age, finding a high correlation between
estimated and observed MBLV. It is important to note
that a certain amount of menstrual fluid is lost for MBLV
measurement. Women lose blood not captured by
sanitary items when changing them, or when clothes are
soaked [19,29,30]. Therefore, MBLV measurement as
determined by the alkaline-hematin-method might not
reflect actual MBLV. However, women perceive this
amount of blood and are able to account for it in their
diary. With this in mind, a menstruation diary could
be a better descriptor of blood loss, a possibility which is
reflected by the slightly higher correlations between esti-
mated values and patients/investigators assessment com-
pared to the correlation between measured values and
patients/investigators assessment (Table 4). Given a large
number of days and women, single events of a larger
fraction of ‘lost’ blood average out.
Limitations
As a statistical model, our method does not provide
precise blood loss measurement. In studies where MBLV
is the primary efficacy outcome, the alkaline-hematin-
method will remain the standard, although that method
does not account for blood loss outside sanitary pro-
tection. Moreover, while we only tested our model in a
single trial, further studies will be needed to verify repro-
ducibility of this model.
Another limitation of our work is the narrowly defined
patient population. Only patients with baseline bleeding
problems like excessive, frequent or prolonged bleeding
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will still need to be performed. Nevertheless, since MBLV
is of special interest in patients complaining about bleed-
ing problems, our results remain clinically meaningful.
Explicit estimation of patient specific effects should be
possible (e.g., from baseline data) and would also be of
clinical interest. However, the approach to estimate the
random patient effects turned out to be inappropriate for
the kind of studies available, because patients had differ-
ent bleeding amounts at baseline and under treatment.
So a number of women exclusively used HEAVY and
NORMAL BI at baseline, but mostly and sometimes
exclusively LIGHT and SPOTTING under treatment,
foiling any estimation. Examination of patient specific
effects should thus be performed in a healthy population
or minimally in patients with stable bleeding patterns.
A number of additional parameters influencing assess-
ment of BI (e.g. hormone levels / ovulation [31]) were not
evaluated in this analysis.
Conclusions
We propose a statistical model for estimating MBLV in
women suffering from prolonged or excessive menstrual
blood loss. The model encompasses entries from bleed-
ing diaries, laboratory parameters and age. The results
correlated well with data derived by the alkaline-hematin-
method and can be used to estimate MBLV in clinical
studies and during routine gynecological counseling.
Additional file
Additional file 1: Appendix Tables.
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